• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Tarsus Pharmaceuticals Inc (NQ: TARS )

    37.03 +0.18 (+0.49%)
    Streaming Delayed Price Updated: 4:00 PM EDT, May 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 679,559
    Open 37.00
    Bid (Size) 35.00 (3)
    Ask (Size) 37.00 (1)
    Prev. Close 36.85
    Today's Range 36.35 - 37.85
    52wk Range 12.57 - 40.40
    Shares Outstanding 20,574,104
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire

    Performance

    YTD
    +83.68%
    +83.68%
    1 Month
    +5.17%
    +5.17%
    3 Month
    +31.08%
    +31.08%
    6 Month
    +131.29%
    +131.29%
    1 Year
    +137.52%
    +137.52%

    More News

    Read More
    Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) is a Stock Spotlight on 4/15
    Via Investor Brand Network
    Tarsus to Participate at Upcoming Investor Conferences
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    A Glimpse Into The Expert Outlook On Tarsus Pharmaceuticals Through 4 Analysts
    Via Benzinga
    Earnings Scheduled For February 27, 2024
    Via Benzinga
    Tarsus Pharmaceuticals's Earnings: A Preview
    Via Benzinga
    Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    Tarsus Announces Pricing of $100.0 Million Public Offering
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    Tarsus Announces Proposed $100.0 Million Public Offering
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    Tarsus Pharmaceuticals - Mixed Projections
    Via Talk Markets
    Recap: Tarsus Pharmaceuticals Q3 Earnings
    Via Benzinga
    ICU Medical To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday
    Via Benzinga
    Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) Making Surprising Moves in Monday Session
    Via Investor Brand Network
    SoFi Technologies Posts Q4 Earnings, Joins Cardlytics, McGrath RentCorp And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Tarsus Pharmaceuticals Stock Scores Relative Strength Rating Upgrade
    Via Investor's Business Daily
    Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    HC Wainwright & Co. Maintains Buy Rating for Tarsus Pharmaceuticals: Here's What You Need To Know
    Via Benzinga
    Big Stocks Moving Higher On Friday: Synaptics Reports Q1 Beat; Joins Lyft, Hologic, Blink Charging
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Wynn Resorts Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) Making Surprising Moves in Friday Session
    Via Investor Brand Network
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.